Regardless of the specific screening option chosen, what is clear is that the inclusion of NT measurements optimizes Down syndrome screening.
The aim of the "FASTER" (First and Second Trimester Evaluation of Risk) study was slightly different: to compare first- and second-trimester testing for Down syndrome.1 The first-trimester approach was the same as the BUN trial, but results were withheld from a patient until second-trimester serum analyte results were available-unless the NT measurement was extremely elevated and the fetus had a cystic hygroma. More than 38,000 women from around the country participated in FASTER. The study found that both first- and second-trimester screening could detect around 85% of fetuses with Down syndrome, but that the screen-positive rate to achieve this detection efficiency was one third lower with first-trimester screening (see Table). They also noted that combining first- and second-trimester testing could yield even better results. A stepwise integrated approach provides patients the results of the first-trimester screen so they have the option of a CVS. It then combines the results of first- and second-trimester screening to produce a final risk assessment. This approach detected 95% of Down syndrome fetuses, for an overall 4.9% screen-positive rate.
Thus, patients now have a menu of options for Down syndrome screening. The advantages of first-trimester screening were articulated in an editorial accompanying the FASTER publication by Contemporary OB/GYN's long-term Editorial Board member Dr. Joe Leigh Simpson.3 He pointed out that earlier detection of increased Down syndrome risk permitted CVS, which is quite safe in experienced hands, as well as earlier terminations for patients who chose to abort affected pregnancies. Such earlier terminations are more private and safer. Thus, use of either first-trimester screening alone or the stepwise integrated option may well be the optimal approach.
No link found between antenatal corticosteroids and child neurodevelopment
April 25th 2024A recent study found no link between antenatal corticosteroid administration and adverse neurodevelopmental outcomes in children aged 6 years or older, offering reassurance for late preterm delivery practices.
Read More
Hyperoxygenation use not linked to neonatal outcomes
April 23rd 2024Recent research evaluated the impact of maternal hyperoxygenation on neonatal Apgar scores, revealing no significant enhancement in outcomes among women with pathologic fetal heart rate tracing and suggesting limited efficacy of hyperoxygenation therapy in this context.
Read More
The benefits of concurrent fetal and maternal heart rate monitoring
April 15th 2024A recent study revealed that employing maternal heart rate monitoring alongside fetal heart rate monitoring during labor significantly decreases the incidence of neonatal encephalopathy and severe neonatal acidemia.
Read More
How vitamin C intake in pregnant smokers impacts offspring airway function trajectory
April 12th 2024Investigating the impact of prenatal vitamin C supplementation on lung function and wheeze occurrence in offspring of pregnant smokers, revealing insights into mitigating respiratory risks.
Read More